23948sdkhjf

Helena Strigård: The rise of the community

| Av Helena Strigård | Tipsa redaktionen

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

With one decade coming to an end, and another one dawning, trends somehow emerge clearer to us. For a brief moment in time, we take on the spectacles of an outsider to the present, and that is when the many tiny incremental changes occurring over a long period of time summarizes in front of our eyes.

Läs också: Anders Blanck: "Coronakrisens lösning är global"

I first stepped into the Swedish life science pond over two decades ago. Or, one might say, I dipped my toes into it. As a 16 year old, I was not very aware of overarching trends when I choose my career path as a biotech-student in Uppsala. The local gymnasium had recently introduced biotech as a program, which was unique at the time. There was something enticing and futuristic about the whole field, and I was a 100% determined this was what I wanted to do and a 100% ignorant of how.

I often go back to think about these early years of my acquaintance with life sciences since it was such a coincidence that I got to start my adult life in an era when this field was flourishing in my hometown, and now, twenty years later, I am on the front row to witness and sense how it is truly flourishing again. But in such a different way. And this is what emerges when you zoom out.

The number of people employed within the life science sector of Sweden is now back to the levels of the 90’s. Status quo, one might think. No. Far from it! The pace of the reshaping and restructuring which has taken place is swirling. From a number of giants dominating the scene to thousands of small actors. Where did they all come from? How is it that they are now together constituting a life science sector of the same magnitude as during the era of big pharma? And how do they manage to build successful businesses in such a complex field demanding competences ranging wider than any other sector. You need people skilled in science, regulatory issues and business development. If you are ten people, or even less, there is no way to do that. Or, is there..?

Apparently, yes. Against all odds, because so many things are not really moving in the right direction right now on a national level concerning the conditions for growing your life science company in Sweden.

I can´t help thinking of the reaction of General Pryde looking up into the sky full of the most random mix of rebell ships in the recent and final episode of Star Wars, expressing his surprise:

– Where did they all come from? The rebels don´t have a navy!

Läs också: Biotech-anställda ska kunna jobba i vården

– It is not a navy, sir. It appears that it is people.

In this saga (spoiler alert), the rebels finally defeated the empire because they stayed connected somehow. When it mattered most, they came together and answered the call. It escaped the minds of the imperial star fleet generals how this mish mash of tiny actors could become such a force to count on. To their knowledge, the scattered remnants of rebel forces

did not have the means to organize themselves. No larger structure visible to the eye. Not enough resources by far to take on the competition.

This odd analogy is remarkably true also for Swedish life sciences of today. The many incremental changes which has happened during the last decade summarizes to what is now an utterly effective sharing of resources. Not every function needs to be kept in-house. No energy needs to be spent on hierchial layers. The experiences of one brilliant mind is generously transferred to another one, accumulating a bank of know-how similar to what can otherwise only be seen in huge corporations with a long history and thousands of employees. And don´t forget. The entrepreneurs of Swedish life sciences has a secret weapon. Their vision. Their hope. Their dedication and devotion to doing something they believe in. In the end, life sciences is about saving people´s lifes, isn´t it?

What we are witnessing now is nothing less but the rise of the community. A new era. One in which the small actors can build capacity jointly in a new and intelligent way.

Now, there is no intergalactic war going on between the international big pharmas and the rebel entrepreneurs of Swedish life sciences. Quite the opposite. In fact, they never needed each other more! The new community-based business model that enables small companies to grow by staying connected to each our and sharing resources still requires the big players. They have critical knowledge of what it is actually like out there, on the global market. How too scale up and jump into light speed when you grow out of your local galaxy.

Yet, something has shifted in the interdependence between young, small companies and the international biggies, and that is what I want to capture. With the community growing stronger, you may dare to take on larger challenges. Even though you might not have the experience yourself on how to successfully handle negotiations with big pharma scouts, how to attract intelligent international capital, how to make your market-entry over-seas - the community is there to support you. To help you speak up for yourself and get those good terms. To avoid pitfalls. All the Skywalkers, sorry I meant entrepreneurs, who walked the same path before you are there to help and share their wisdom.

The giant star cruisers of biotech and pharma are difficult to navigate. They move slowly, while the world is rapidly changing around them. And they know this. They need the innovative power of the young ones. This is not something to fear. It is something to be explored. Just make sure you are fitted properly and don´t hesitate to turn to the community for help. Whether you are facing the opportunity to dock into a large company structure, to have them invest in you or to enter into collaborations.

The new decade has just begun and I am thrilled to continue the mission of SwedenBIO to support this era of community-based life sciences. In ten years from now, I am sure nothing will look the same.

May the entrepreneurial force be with you!

Håll dig uppdaterad med Life Science Sweden
Är du prenumerant? Bli prenumerant

Med en prenumeration får du obegränsad tillgång till webbtidningen. Läs webbtidningen online.

Kommentarer (0)

JOBB I FOKUS

Startsidan just nu

Ökad dödlighet av klorokin och hydroxyklorokin vid covid-19

Här är vaccinkandidaterna mot coronaviruset

Totalt finns det idag tio pågående kliniska studier om vaccinkandidater mot det nya coronaviruset.

Remdesivir förkortade vårdtid vid covid-19

Det antivirala läkemedlet remdesivir var bättre än placebo i att korta vårdtiden för svårt covid-19-sjuka, enligt studiedata som nu publicerats.

Jobb & Karriär
Ny chef på Bactiguard

I augusti tillträder Gabriella Björknert Caracciolo som ny CFO samt vice vd på Bactiguard.

7

Björn Olsen: "Det kommer nog ingen andra våg av covid-19"

Det är dags att sluta se på det nya coronaviruset som om det vore en influensa. Life Science Sweden har intervjuat infektionsprofessorn Björn Olsen om flockimmunitet och hur viruset kommer påverka oss i framtiden.

Fästingprotein prövas mot covid-19

Ett skotskt biotechföretag och forskare i Oxford har inlett ett samarbete för att ta reda på om ämnen som fästingar utsöndrar kan användas som behandling vid covid-19.

Nyhetsbrev

Ledare
Framgången kommer efter många misslyckanden

De allra flesta av de idéer och strategier mot covid-19 som man nu jobbar med kommer att gå i stöpet, men det kan räcka med att en enda fungerar, skriver Samuel Lagercrantz.

Arkiv

Modernas covidvaccin visade positiva resultat

I en mindre studie bildades antikroppar hos studiedeltagare som fick pröva vaccinkandidaten mRNA-1273 mot covid-19.

Läkemedelsverket förbjuder ett till covidtest

Plus

De tar fram blodprov för pankreascancer

Efter sex års arbete ska företaget Immunovia i höst lansera sin teknik som syftar till att kunna identifiera cancer i bukspottkörteln i ett tidigt stadium.

Krönika
Björn Arvidsson: "Kriser visar vad som är viktigt - på riktigt"

Vore det inte fantastiskt att låta de privata aktörerna i större utsträckning bidra till att lösa samhällets utmaningar, skriver Björn Arvidsson, verksamhetsledare för STUNS Life Science, i en krönika.

Krönika
Diagnostiken är mitt i händelsernas centrum

Intresset för diagnostik får inte svalna när coronapandemin väl är över, det skriver Therese Hazelius, vd för Swedish Labtech, i en krönika.

Röntgen visar hur coronaviruset förökar sig

3

Ledare
Flockimmunitet och flockmentalitet

Reaktionerna som följde på de 22 forskarnas förra debattinlägg lät ibland som tagna från satirprogrammet Kina-TV, skriver Life Science Swedens chefredaktör Samuel Lagercrantz som gör en tillbakablick.

Jobb & Karriär
Abigo får ny vd

Möjlig koppling mellan covid-19 och Kawasakiliknande sjukdom hos barn

Forskare i Italien har i en fallstudie sett att barn med tidigare covid-19-sjukdom insjuknat i en Kawasakiliknande-sjukdom. Flera forskare har noterat liknande händelser.

Column
Key lessons from global health research

The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.

Jobb & Karriär
Micropos får ny vd

Finans
Oasmia ska genomföra kostnadsbesparingar

Follicum söker internationellt patentskydd för kräm mot håravfall

3

Krönika
”När faran slår till visar sig vårt innersta jag”

Coronapandemin fyller alla kriterier för att klassas som en ”svart svan”, skriver Anna Törner i en krönika.

Remdesivir kan ges till fler patienter

Europeiska läkemedelsmyndigheten, EMA, har uppdaterat sin rekommendation för användning av remdesivir för svårt sjuka covid-19-patienter.

Moderna får snabbspår för vaccinkandidat mot covid-19

Amerikanska läkemedelsmyndigheten FDA har gett Moderna ett snabbspår för vaccinkandidaten mRNA-1273.

Nascent Invest och Fort Knox investerar i test för bloddoping

Astra Zeneca tar tillbaka rättigheter till brazikumab

Dignitana tecknar avtal med Hartford HealthCare

Synartro genomför nyemission inför artrosstudie

Jobb & Karriär
Kancera rekryterar från Astra Zeneca

Fälttester för covid-19 ska utvärderas

Jobb & Karriär
Biopharma nyrekryterar

Jobb & Karriär
Xvivo byter vd

Hjärt-lungfonden stöder covidforskning

Vetenskapsrådet ska underlätta för fler kliniska studier mot coronaviruset

WWF ska kartlägga Astrazenecas vattenförvaltning

Helena Strigård: The rise of the community

Jobb & Karriär
Biolamina rekryterar ny försäljningschef

Se alla Medlemsnytt

Join us for a webinar on confocal microscopy!

3D Scanning Systems - Innovative Solutions for 3D digitizin

Akut produktion av desinfektionsmedel med hjälp av Busch

Improve your metrology skills, also @home.

Leverans av Busch vakuumsystem till Brasilien

Cleaning and Disinfecting Microscope and Optical Components

Busch Vakuum Solutions levererar till sjukhus i Palestina

Are you working from home?

Busch Vacuum Solutions levererar till sjukhustrailers i USA

Centralisering av vakuum från Busch Vacuum Solutions

Increase efficiency in the lab!

Verifiering vid tillverkning av Ventilatorer

Busch levererar vakuumsystem till akutsjukhus i Madrid

Samarbete mellan Busch i Schweiz och Frankrike mot Corona

Rening av gaser med vakuumteknik från Busch Vacuum Solutions

Optimize measurement plans remotely with free ZEISS CALYPSO

Find what you need from the ZEISS Industrial Quality world.

Biofiltrering med Busch TYR Blåsmaskin

Ny Country Manager PharmaRelations Norge

Perfekt packad skinka med vakuum från Busch

Last week, we introduced ZEISS Lightsheet 7.

Fiskodling med vakuum från Busch Vacuum Solutions

Busch Vacuum Solutions

Energieffektiv produktion med centralvakuum

Stor energibesparing med centralvakuum i förpackningsprocess

Sänd till en kollega

0.104